KRN5500 meets neuropathic pain endpoint

Dara BioSciences Inc. (NASDAQ:DARA) said KRN5500 met the primary endpoint of a decrease from baseline in average pain intensity in a Phase IIa trial to treat neuropathic pain in cancer patients. KRN55...